Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04270890
Other study ID # CO966
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 21, 2018
Est. completion date April 30, 2022

Study information

Verified date February 2020
Source The Clatterbridge Cancer Centre NHS Foundation Trust
Contact Maria Maguire, PhD
Phone 0151 556
Email maria.maguire2@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is applicable to patients undergoing lower lung or abdomen stereotactic ablative body radiotherapy (SABR) treatment. The purpose of the ACE 01 study is to identify if, the volume of healthy tissue within the treatment area and therefore subsequent side effects, can be reduced by using a commercially available abdominal compression device to minimise breathing related movement. The secondary aim will be to assess patient compliance and comfort of thedevice. This will be assessed by asking the patient to complete a 'patient comfort questionnaire'. In addition the radiographers will be asked to complete a 'satisfaction questionnaire' to determine ease and reproducibility of use.


Description:

Stereotactic ablative body radiotherapy (SABR) offers the ability to deliver a high dose of radiotherapy accurately to small tumours. It is an established, effective, non-invasive treatment option for early lung cancers as an alternative to surgery and in the treatment of limited spread of cancer (called oligo-metastatic disease) in the context of clinical trials (CORE, SARON, ABC-07 etc.). In order to deliver a high dose of radiation without damaging the surrounding structures, an accurate map of the tumour and the surrounding organs and their relationship to each other when moving (for e.g. during breathing) is important. This is usually achieved by getting a radiotherapy treatment planning 4 dimensional CT scan (4D-CT). When either the tumour or organ around them (like the lung) are moving excessively it becomes difficult to target the radiation beams and often the only solution is to treat a larger volume which covers the extent of the movement. Treating larger volumes often leads to more toxicity to the surrounding tissues.Therefore managing motion is critical to increasing tumour control probability (TCP) and reducing normal tissue complication probability (NTCP). In this context, the question of reducing the movement caused by breathing, of tumours in the lower lung and upper abdomen (like the liver, adrenals, kidney etc) is an area of intense interest. Various technical and physical methods exist to help improve motion management in patients under going radiotherapy. By limiting the movement, the target volume is smaller and this enables treatment of the tumour to high doses with lesser toxicity as some of the toxicity of radiotherapy is proportionate to the volume treated i.e. lower the volume of treatment lesser the risk of toxicity. Abdominal compression is one such method and is well accepted to be beneficial in reducing tumour motion. However, many of the previous studies require expensive and resource intensive immobilisation devices, costing, in many cases in excess of £10,000. This study will investigate the use of an independent compression device which can be used with any existing immobilisation system and costs in the region of £1,500. If proven to be beneficial this will allow many smaller centres or centres with budget limitations to also achieve the benefits of abdominal compression without extensive resource and cost requirements.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 30, 2022
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - • Radiological or Histologically confirmed lower lobe lung cancer or histologically confirmed metastatic of primary cancer in abdominal organs including liver, pancreas, adrenal which meets criteria for SABR treatment. - Aged 18 years or over - Capacity to understand research proposal and give informed consent Exclusion Criteria: - Tumour sites excluding those previously defined - Rib metastases - Stoma if situated underneath belt - Patients unable to tolerate the abdominal compression belt - Patients with existing abdominal aortic aneurysm (AAA)

Study Design


Intervention

Device:
Abdominal compression belt system
The abdominal compression belt system is provided free of charge from CDR systems, Canada. The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position.

Locations

Country Name City State
United Kingdom Clatterbridge Cancer Centre NHS Foundation Trust Bebington

Sponsors (1)

Lead Sponsor Collaborator
The Clatterbridge Cancer Centre NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure change in treatment volume between freebreathing and abdominal compression scans Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction.
compression belt
2 years
Secondary Reported patient feedback regarding device comfort and compliance of use. The comfort of the device in clinical use will be measured by using a questionnaire that the patient will be asked to complete at initial scanning and then on two subsequent treatments. The results will be collated and analysed to qualitatively measure patient comfort and use of the device 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06152419 - Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project N/A
Recruiting NCT04105647 - Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study N/A
Completed NCT05732350 - Exploratory Drug Interaction Study Between SMIs and DOACs
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Active, not recruiting NCT04396457 - Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 Phase 2
Recruiting NCT06391749 - Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Completed NCT04788147 - Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X) N/A
Not yet recruiting NCT06035731 - Evaluation of the Medical Service by Socio-aesthetics in Oncology N/A
Recruiting NCT03274349 - Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma N/A
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02991677 - Exercise Effect on Chemotherapy-Induced Neuropathic Pain N/A
Completed NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Recruiting NCT04859400 - Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients N/A
Recruiting NCT05948865 - A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT05154474 - Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Not yet recruiting NCT05857995 - Precision Lung Cancer Survivorship Care Intervention N/A
Not yet recruiting NCT03622528 - Quantitative Lung Cancer Screening